Open original FDA record ↗Recall record
- FDA identifier
- Z-0775-2014
- Company in FDA record
- Lab Vision Corporation
- FDA classification date
- Jan 16, 2014
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Reports that the product is not performing as expected. In house testing showed no staining on breast cancer tissues.
Source facts
- Action
- Lab Vision Corporation part of Thermo Fisher Scientific sent an Urgent Medical Device Recall letter dated December 6, 2013, to all affected customers. Revised letters will be sent on January 8, 2014. Changes include that the reagent is an Analyte Specific Reagent (ASR) and not an in vitro diagnostic device in the US. They also clarify that a false positive was reported by a customer and a false negative was confirmed during in house testing. Letters also correct the expiry date from 12/2013 to 03/2015. Data sheet was also updated to eliminate information stating that the presence of ER in breast tumors indicates an increased likelihood of response to estrogen therapy and also that the positive control must be determined by the investigator. If you have any questions, please contact Technical Service at 1-800-522-7270, option 2, option 7.
- Initiated
- 2013-12-06
- Root cause
- Under Investigation by firm
- Terminated
- 2014-02-25
- Distribution
- Worldwide Distribution: US (nationwide) including the states of TX and MA and internationally to: Turkey.
- Recall number
- Z-0775-2014
- Recall status
- Terminated
- CDRH record ID
- 124646
- FDA classified
- 2014-01-16
- Recall event number
- 67065